Genesis Healthcare, Inc. GENNQ
—
0.00
0.00
NaN
as of 24 Sep
- Market cap
- —
- P/E
- 0.0×
Follow GENNQ
| Dec '16 | Dec '17 | Dec '18 | Dec '19 | Dec '20 | |
|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 13.67 | 0.00 |
P/S ratio |
0.07 | 0.01 | 0.02 | 0.04 | 0.01 |
P/FCF ratio |
22.50 | 0.55 | 2.85 | 0.00 | 0.17 |
P/Operating CF |
11.99 | 1.51 | 26.38 | (7.68) | 1.55 |
P/B ratio |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Price to Tangible BV |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
EV/Sales |
0.93 | 0.93 | 0.98 | 0.38 | 0.34 |
EV/EBITDA |
9.53 | 20.98 | 16.69 | 13.14 | 0.00 |
EV/Operating CF |
78.10 | 41.70 | 263.52 | (240.65) | 4.21 |
EV/FCF |
303.03 | 34.18 | 117.14 | (4.27) | 4.25 |
Quick Ratio |
1.08 | 0.91 | 0.83 | 0.63 | 0.19 |
Current Ratio |
1.23 | 1.05 | 0.96 | 0.77 | 0.23 |
Net Debt/EBITDA |
8.82 | 20.65 | 16.28 | 11.80 | (3.32) |
Debt/Assets |
87.17% | 105.14% | 115.12% | 35.51% | 38.86% |
Debt/Equity |
(6.90) | (3.00) | (2.40) | (1.53) | (1.36) |
Asset Turnover |
0.97 | 1.02 | 1.10 | 1.02 | 0.90 |
Operating CF/Net income |
(1.07) | (0.21) | (0.08) | (0.49) | (5.35) |
Capex/Depreciation |
(0.20) | 0.04 | 0.10 | (3.22) | (0.03) |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| 9.49% | 48.04% | 12.63% | (0.93%) | 5.25% | |
| (1.08%) | (10.96%) | (5.20%) | 0.33% | (1.35%) | |
ROIC |
4.49% | (7.21%) | 1.58% | 1.09% | (267.94%) |
Return on Tangible Assets |
(1.61%) | (16.76%) | (8.25%) | 2.03% | 2.96% |
Average Days of Receivables |
52.98 | 49.19 | 45.67 | 45.38 | 39.89 |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Selling, General and Administrative Expense of Revenue |
64.58% | 62.38% | 61.61% | 66.07% | 71.62% |
Intangible Assets out of Total Assets |
0.11 | 0.05 | 0.05 | 0.04 | 0.04 |
Share Based Compensation of Revenue |
0.15% | 0.18% | 0.18% | 0.16% | 0.17% |
Graham Net Nets |
(13.75) | (69.03) | (45.58) | (27.94) | (81.12) |
Graham Number |
11.47 | 49.51 | 32.58 | 0.00 | 11.90 |
Earnings Yield |
(16.33%) | (718.82%) | (197.46%) | 7.32% | (126.10%) |
Free Cash Flow Yield |
4.45% | 183.47% | 35.08% | (229.47%) | 581.72% |
Revenue per Share |
63.78 | 57.04 | 49.27 | 42.56 | 34.92 |
Operating CF per Share |
0.76 | 1.28 | 0.18 | (0.07) | 2.82 |
Capex per Share |
(0.56) | 0.28 | 0.23 | (3.70) | (0.03) |
Free Cash Flow per Share |
0.20 | 1.56 | 0.41 | (3.76) | 2.79 |
Cash per Share |
1.06 | 0.97 | 1.29 | 1.00 | 2.70 |
Shareholders Equity per Share |
(8.12) | (17.83) | (20.24) | (10.09) | (10.39) |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
(8.12) | (17.83) | (20.24) | (10.09) | (10.39) |
Free Cash Flow |
17.62 | 146.93 | 41.81 | (403.75) | 312.32 |
Working Capital |
201.43 | 40.71 | (36.59) | (242.32) | (2,975.58) |
Capital Expenditures |
(50.74) | 26.48 | 23.22 | (396.58) | (3.41) |
Net Current Asset Value |
(5,450.40) | (5,528.09) | (5,432.86) | (4,915.86) | (4,355.36) |
EV/EBIT |
17.64 | 0.00 | 70.93 | 212.72 | 0.00 |
Capex to Sales |
0.01 | 0.00 | 0.00 | 0.09 | 0.00 |
Net Profit Margin |
(1.12%) | (10.77%) | (4.73%) | 0.32% | (1.51%) |
Price to Operating Income |
1.31 | 0.00 | 1.73 | 21.70 | 0.00 |
| Other line items | |||||
Depreciation/Fixed assets |
0.07 | 0.18 | 0.08 | 0.13 | 0.11 |
Cash ROIC |
(83.98%) | (95.58%) | (95.83%) | (142.52%) | (93.18%) |
Accounts Receivable Turnover |
7.07 | 6.91 | 7.39 | 7.67 | 7.86 |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Average Receivables |
810.75 | 778.12 | 673.43 | 595.18 | 497.28 |
Average Payables |
246.21 | 272.13 | 260.21 | 236.59 | 224.87 |
Average Assets |
5,919.58 | 5,283.53 | 4,525.74 | 4,462.88 | 4,362.19 |
Average Common Equity |
(674.79) | (1,205.16) | (1,862.50) | (1,563.72) | (1,122.41) |
Columns are period end dates